Sentman CL - Search Results

1

Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy.

Rajasekaran K, Riese MJ, Rao S, Wang L, Thakar MS, Sentman CL, Malarkannan S. Rajasekaran K, et al. Among authors: sentman cl. Front Immunol. 2016 May 12;7:176. doi: 10.3389/fimmu.2016.00176. eCollection 2016. Front Immunol. 2016. PMID: 27242783 Free PMC article. Review.

2

Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity.

Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R, Wang L, Nesbeth Y, Durant Y, Gewirtz AT, Sentman CL, Kedl R, Conejo-Garcia JR. Cubillos-Ruiz JR, et al. Among authors: sentman cl. J Clin Invest. 2009 Aug;119(8):2231-44. doi: 10.1172/JCI37716. Epub 2009 Jul 13. J Clin Invest. 2009. PMID: 19620771 Free PMC article.

3

Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer.

Barber A, Zhang T, Sentman CL. Barber A, et al. Among authors: sentman cl. J Immunol. 2008 Jan 1;180(1):72-8. doi: 10.4049/jimmunol.180.1.72. J Immunol. 2008. PMID: 18097006

4

Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.

Barber A, Sentman CL. Barber A, et al. Among authors: sentman cl. J Immunol. 2009 Aug 15;183(4):2365-72. doi: 10.4049/jimmunol.0900721. Epub 2009 Jul 22. J Immunol. 2009. PMID: 19625653 Free PMC article.

5

Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.

Barber A, Rynda A, Sentman CL. Barber A, et al. Among authors: sentman cl. J Immunol. 2009 Dec 1;183(11):6939-47. doi: 10.4049/jimmunol.0902000. Epub 2009 Nov 13. J Immunol. 2009. PMID: 19915047 Free PMC article.

6

TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells.

Iyori M, Zhang T, Pantel H, Gagne BA, Sentman CL. Iyori M, et al. Among authors: sentman cl. J Immunol. 2011 Sep 15;187(6):3087-95. doi: 10.4049/jimmunol.1003879. Epub 2011 Aug 10. J Immunol. 2011. PMID: 21832159 Free PMC article.

7

An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.

Zhang T, Wu MR, Sentman CL. Zhang T, et al. Among authors: sentman cl. J Immunol. 2012 Sep 1;189(5):2290-9. doi: 10.4049/jimmunol.1103495. Epub 2012 Jul 30. J Immunol. 2012. PMID: 22851709 Free PMC article.

8

Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.

Zhang T, Sentman CL. Zhang T, et al. Among authors: sentman cl. J Immunol. 2013 Mar 1;190(5):2455-63. doi: 10.4049/jimmunol.1201314. Epub 2013 Jan 25. J Immunol. 2013. PMID: 23355740 Free PMC article.

9

Bispecific T-cell engagers for cancer immunotherapy.

Huehls AM, Coupet TA, Sentman CL. Huehls AM, et al. Among authors: sentman cl. Immunol Cell Biol. 2015 Mar;93(3):290-6. doi: 10.1038/icb.2014.93. Epub 2014 Nov 4. Immunol Cell Biol. 2015. PMID: 25367186 Free PMC article. Review.

10

B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity.

Wu MR, Zhang T, Gacerez AT, Coupet TA, DeMars LR, Sentman CL. Wu MR, et al. Among authors: sentman cl. J Immunol. 2015 Jun 1;194(11):5305-11. doi: 10.4049/jimmunol.1402517. Epub 2015 Apr 24. J Immunol. 2015. PMID: 25911747 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

116 results

Search Page

Filters